AU2009280369A1 - The treatment of hearing loss - Google Patents

The treatment of hearing loss Download PDF

Info

Publication number
AU2009280369A1
AU2009280369A1 AU2009280369A AU2009280369A AU2009280369A1 AU 2009280369 A1 AU2009280369 A1 AU 2009280369A1 AU 2009280369 A AU2009280369 A AU 2009280369A AU 2009280369 A AU2009280369 A AU 2009280369A AU 2009280369 A1 AU2009280369 A1 AU 2009280369A1
Authority
AU
Australia
Prior art keywords
noise
adenosine receptor
receptor agonist
adenosine
exposure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009280369A
Other languages
English (en)
Inventor
Gary David Housley
Peter Rowland Thorne
Srdjan Vlajkovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of AU2009280369A1 publication Critical patent/AU2009280369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009280369A 2008-08-11 2009-08-11 The treatment of hearing loss Abandoned AU2009280369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ57046908 2008-08-11
NZ570469 2008-08-11
PCT/NZ2009/000164 WO2010019057A1 (en) 2008-08-11 2009-08-11 The treatment of hearing loss

Publications (1)

Publication Number Publication Date
AU2009280369A1 true AU2009280369A1 (en) 2010-02-18

Family

ID=41669060

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009280369A Abandoned AU2009280369A1 (en) 2008-08-11 2009-08-11 The treatment of hearing loss

Country Status (8)

Country Link
US (1) US20110207689A1 (cg-RX-API-DMAC7.html)
EP (1) EP2328577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011530585A (cg-RX-API-DMAC7.html)
CN (1) CN102159209A (cg-RX-API-DMAC7.html)
AU (1) AU2009280369A1 (cg-RX-API-DMAC7.html)
CA (1) CA2733918A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011001551A (cg-RX-API-DMAC7.html)
WO (1) WO2010019057A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6279496B2 (ja) * 2015-01-08 2018-02-14 積水化成品工業株式会社 発泡粒子及び発泡成形体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248770A (en) * 1984-10-26 1993-09-28 The United States Of America, As Represented By The Department Of Health And Human Services Molecular probes for adenosine receptors
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
SE9401499D0 (sv) * 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
WO1997037667A1 (en) * 1996-04-10 1997-10-16 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions

Also Published As

Publication number Publication date
JP2011530585A (ja) 2011-12-22
CA2733918A1 (en) 2010-02-18
EP2328577A1 (en) 2011-06-08
WO2010019057A1 (en) 2010-02-18
MX2011001551A (es) 2011-03-29
EP2328577A4 (en) 2011-10-19
CN102159209A (zh) 2011-08-17
US20110207689A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
Shoji et al. Differential protective effects of neurotrophins in the attenuation of noise-induced hair cell loss
Pourbakht et al. Ebselen attenuates cochlear damage caused by acoustic trauma
Sergi et al. Cisplatin ototoxicity in the guinea pig: vestibular and cochlear damage
KR101429735B1 (ko) 와우각 흥분독성에 의해 유발된 이명의 치료를 위한 nmda 수용체 길항제의 용도
US8507525B2 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US10966940B2 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
Manalo et al. Adenosine A2B receptor: A pathogenic factor and a therapeutic target for sensorineural hearing loss
Wong et al. Post exposure administration of A1 adenosine receptor agonists attenuates noise-induced hearing loss
Kempfle et al. Experimental drugs for the prevention or treatment of sensorineural hearing loss
Bako et al. The ototoxic effect of locally applied kanamycin and furosemide in guinea pigs
JP2015511242A (ja) 病変性前庭障害の治療に使用するカルシニューリン阻害剤
Bielefeld Protection from noise-induced hearing loss with Src inhibitors
JP2008513407A (ja) 中枢神経由来の神経障害性疼痛の治療用テトロドトキシンおよびその誘導体
US20110207689A1 (en) The treatment of hearing loss
CN113855803B (zh) Prmt5抑制剂在用于制备听力保护药物中的用途
US12162935B2 (en) Regimens, compositions and methods with capsaicin and TNF-alpha inhibitor
Öntepeli et al. Audiometry results and TEOAE and DPOAE amplitudes in men taking a phosphodiesterase type 5 inhibitor for erectile dysfunction
Tabuchi et al. The effects of A1 and A2A adenosine receptor agonists on kainic acid excitotoxicity in the guinea pig cochlea
Escabi et al. Noise-Induced Hearing Loss and Drug Therapy: Basic and Translational Science
Perez et al. Local drug delivery for inner ear therapy
Lutze The Role of the Mitogen Activated Protein Kinase Pathway in Cisplatin and Noise-Induced Hearing Loss
Magarinos et al. frontiers REVIEW in Aging Neuroscience published: 21 April 2015 doi: 10.3389/fnagi. 2015.00058

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period